ERCC1在结肠癌化疗敏感性中的研究进展  

Research progress of ERCC1 in chemosensitivity of colorectal cancer

作　　者：尹思源 姜洋[1] YIN Siyuan;JIANG Yang(China-Japan Union Hospital of Jilin University,Changchun 130033,China)

机构地区：[1]吉林大学中日联谊医院,吉林长春130033

出　　处：《中国实验诊断学》2025年第2期230-234,共5页Chinese Journal of Laboratory Diagnosis

基　　金：吉林省卫生科研人才专项项目(2023SCZ21)。

摘　　要：ERCC1作为一种关键性基因,主要通过修复铂类化疗药物引起的DNA损伤而在影响结肠癌化疗敏感性的过程中发挥效果。根据现阶段研究表明,ERCC1的高表达通常预示着化疗的耐药性以及较差的预后。此外,ER-CC1的表达水平也受到ZEB2等某些其他因素的调控和影响。在临床方面,可以通过免疫组化等方法对ERCC1进行检测,为医生预测患者化疗疗效并提供个体化的治疗方案提供理论依据。在未来通过联合治疗等方法,有望显著提高化疗敏感性,为结肠癌的精准治疗提供新的方法和视野。本文主要从ERCC1的结构与生理功能,诱导结肠癌化疗耐药的分子机制以及其临床应用价值与未来潜力三个方面综述其在结肠癌化疗敏感性方面研究的最新进展。As a key gene,ERCCl primarily exerts its effects on CRC chemosensitivity by repairing DNA damage caused by platinum-based chemotherapeutic agents.Current studies indicate that high ERCCl expression is often asso-ciated with chemotherapy resistance and poor prognosis.Additionally,ERCC1 expression is regulated and influenced by factors such as ZEB2.Clinically,ERCC1 can be detected using methods such as immunohistochemistry,providing a the-oretical basis for predicting chemotherapy efficacy and guiding personalized treatment plans.In the future,combination therapies and other strategies hold promise for significantly enhancing chemotherapy sensitivity,offering new approa-ches and perspectives for the precise treatment of CRC.This article reviews the latest advancements in the research on ERCC1(Excision Repair Cross-Complementation Group 1)in colorectal cancer(CRC)chemosensitivity from three per-spectives:its structure and physiological functions,molecular mechanisms underlying chemotherapy resistance,and its clinical applications and future potential.

关 键 词：ERCC1基因 结肠癌 化疗敏感性 耐药机制 

分 类 号：R735.35[医药卫生—肿瘤]